- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01019681
Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia
Umbilical Cord Blood Stem Cell Injection for Critical Limb Ischemia
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Umbilical cord blood is a safe alternative source of stem cells used for decades in hematopoietic stem cell transplants for malignancies. There is also a reported decreased incidence of acute GVHD compared to matched unrelated donor transplants.A cord blood registry will be searched for suitable units with compatibility in the ABO and HLA systems. The minimum total nucleated cell dose required which would be 1.0 x 107/kg, and one unit of cells will be procured to meet this requirement. Although it is likely that the transplanted cord blood cells will be rejected over time, we hypothesize that while they remain in the host's tissue these cells will be producing and releasing cytokines, growth factors and other humoral factors that might promote vasculogenesis by stimulating endogenous stem cells and endothelial cells. Since there is no need to collect the patient's own stem cells, the patient's cardiovascular system will not be subjected to any stress due to the leukapheresis procedure itself. No injections of exogenous growth factors, which have been associated with thrombosis, would be required to mobilize the patient's own stem cells. The procedure could conceivably even be performed in its entirety on an outpatient basis.
A total of 25 patients will be enrolled in the study. Patients will be followed for 24 months after the procedure with evaluation visits one day after the transplant and then at one month, six, twelve and twenty four months post-treatment. The visit one day after the transplant will involve a history and physical with a leg exam, a CBC and a chemistry panel to evaluate for possible infection, or other adverse event.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Northwestern University
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Atherosclerotic ischemic peripheral vascular disease or Thromboangiitis Obliterans with Critical Limb Ischemia (Fontaine stages III and IV)
Participant must match either a or b
- Ankle brachial index (ABI) ≤ 0.7
- Doppler waveforms at posterior tibial artery and dorsalis pedis artery are monophasic with toe pressure < 30 mmHg.
- A non-surgical candidate for revascularization e.g. prior vascular reconstruction, inability to locate a suitable vein for grafting, diffuse multi- segment disease, or extensive infra-popliteal disease not amenable to a vascular graft.
- Age > 18 years old.
- The non-index leg may be treated only in the event and it full fills the same eligibility criteria and exclusion criteria used in this protocol for the treatment leg.
- Patients must be on maximal tolerated medical therapy for PVD including A) Cessation of smoking B) Referral to endocrinologist for control of HgA1c to < 7.0 mg/dl, control of hyperlipidemia with statins or other anti-hyperlipidemic drugs as indicated, control of hypertension as indicated C) Antiplatelet therapy with aspirin and / or cilostazol (unless medically contraindicated, e.g. bleeding or allergy)
Exclusion Criteria:
- Popliteal vascular entrapment syndrome
- Lower extremity infection or infected ulcer
- Hypercoagulable state
- HIV positive
- HBsAg positive
- Uncontrolled arrhythmia, that is, persistence of an arrhythmia despite medical therapy
- Unstable angina
- Thrombocytopenia < 50,000/ul
- Leukemia or myelodysplasia
- Allergy to E coli or its products
- Patients with metal in their bodies cannot undergo MRIs (MRA). Therefore, patients with, cochlear implants, or aneurysm clips are not eligible. Coronary artery stents are not a contraindication. Patients with pacemakers are still candidates provided they have normal creatinine (< 1.1 mg/dl) and can receive contrast dye (no allergy) for angiogram instead of MRA. MRI/MRA does not need to be repeated if a prior MRA or Angiogram Demonstrates inoperable disease.
- Patients who are pregnant
- Poorly controlled diabetes will not be a cause for exclusion but patient must see endocrinologist for better control
- Current malignancy, except squamous cell or basal cell skin cancers thought to be easily controlled.
- AST, ALT, or bilirubin more than twice the upper limit of normal.
- WBC < 2.5 / ul.
- Any patient who is actively bleeding, including blood on urine dipstick or fecal occult blood.
- Patient is on chemotherapy or other immuno-suppressive medications such as steroids, cellcept, cyclosporine, cytoxan, azathioprine, rituxan, humira or remicade.
- Donor is HLA homozygous and shares that HLA haplotype with the recipient (a different donor will have to be found)
- Patients diagnosed with Thromboangiitis Obliterans (Buerger's Disease) who are smokers and are unwilling or unable to quit smoking
- A) Patients with a myocardial infarction within the last 30 days or left ventricular ejection fraction < 35% B) Patients with a history of malignancy in the last 5 years (other than basal cell carcinoma or carcinoma in situ) C) Patients with a CVA within the last 6 months D) Patients with a HbA1c level > 7.0%
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: UBC injection into one leg of PVD pt
25 participants with severe peripheral vascular disease in leg(s) and they do not qualify for surgical treatment.
|
The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure. Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois).
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Ankle brachial index (ABI), a 15% increase will be considered improvement
Tijdsspanne: Pre-transplant, 1, 6, 12 and 24 months after
|
Pre-transplant, 1, 6, 12 and 24 months after
|
|
Healing of ischemic ulcers
Tijdsspanne: Pre-transplant, 1, 6, 12 and 24 months after
|
Pre-transplant, 1, 6, 12 and 24 months after
|
|
Decreased pain level as reported by the patient
Tijdsspanne: Pre-transplant, 1, 6, 12 and 24 months after
|
Pre-transplant, 1, 6, 12 and 24 months after
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
SF-36 quality of life (QOL)
Tijdsspanne: Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
|
Walking Impairment Questionnaire
Tijdsspanne: Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
|
Increase in pain free ambulation time on treadmill by more than 25%
Tijdsspanne: Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
|
Increase in four meter walk or six minute walk by more than 25%
Tijdsspanne: Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
Pre-transplant, 1, 6 , 12, and 24 months after HSC transplant
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Richard Burt, MD, Northwestern University and Northwestern Memorial Hospital
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- PVD.Cord.Blood.2008
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .